Ther-Rx, Perrigo Launch Gynazole-1 Single-dose Yeast Infection Treatment

The pharmaceutical packaging and product is indicated for local treatment of yeast infections in non-pregnant women.

Ther-Rx Corp., a women's health-focused pharmaceutical company and subsidiary of K-V Pharmaceutical Company (OTCQB Marketplace:  KVPHA/KVPHB), and Perrigo Company (Nasdaq: PRGO; TASE) announced today that Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%), indicated for the local treatment of yeast infections (vulvovaginal candidiasis infections caused by Candida) in non-pregnant women1, is now available for prescribing.  Gynazole-1 is available at major national and regional retail pharmacy chains across the country.

No votes yet
Syndicate content